Johnson & Johnson Starts Downsizing Plan, PCH Integration Stays On Track
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson executives are touting the strength of the firm's consumer products businesses as they implement a plan to generate up to $1.6 billion in savings through consolidations and layoffs in J&J's pharmaceutical and medical device operations
You may also be interested in...
J&J’s Consumer Sales Buoyed By Listerine In Third Quarter
Johnson & Johnson's Listerine mouthwash brand achieved double-digit growth in its most recent quarter, fueled by international sales and the recent U.S. launch of Whitening Quick Dissolving Strips, the firm said Oct. 16
J&J Sees International OTC Presence, Pfizer Pickups As Growth Engines
Johnson & Johnson's over-the-counter version of the antihistamine Zyrtec will not have a period of marketing exclusivity following its planned year-end launch and likely will face competitors immediately, the firm said during a June 7 meeting with financial analysts in New Brunswick, N.J
FTC Views Testimonials As Efficacy Claims, Senior Attorney Warns
The Federal Trade Commission's senior staff attorney for advertising practices recommends firms stay away from using consumer testimonials to assert the benefits of their products